Objective: To evaluate the association between maternal plasma thrombomodulin levels and infant birth weights in pregnancy-induced hypertension. Study design: Plasma thrombomodulin levels were measured in 80 pregnant women living in the Trakya region of Turkey. Of these patients, 30 were with severe preeclampsia, 10 with HELLP syndrome, 10 with eclampsia, and 30 were normotensive healthy pregnant women. Plasma thrombomodulin levels were determined by the enzyme-linked immunosorbent assay method. The correlation analysis between thrombomodulin and birth weight and placental weights was done using analysis of variance and Bonferroni test (significance at P < .05). Kruskal-Wallis statistical analysis was performed in comparison of the descriptive and laboratory data (significance at P < .05). Results: The plasma thrombomodulin values in hypertensive disorders in pregnancy were found to be highly correlated with the infant birth weights (P < .001). In HELLP syndrome, the highest thrombomodulin levels (94.69 + 10.41 ng/mL) were associated with the lowest infant birth weight (1509.70 + 187.55 g) in the study population. Thrombomodulin in eclampsia (81.37 + 3.59 ng/mL) showed an association with infant birth weight (2078 + 132.65 g). Although thrombomodulin levels in severe preeclampsia (67.15 + 3.72 ng/mL) were associated with the values (1748.20 + 132.62 g) in infant birth weight, thrombomodulin levels of the control group demonstrated the mean (48.06 + 2.45) with the highest infant birth weight (3228.85 + 84.83) in the total group. Conclusion: Elevated plasma thrombomodulin levels in hypertensive disorders of pregnancy were well correlated with related infant birth weights of these pathologies. Plasma thrombomodulin levels might point out placental vascular endothelial damage reflecting on infant birth weights.
Introduction
Preeclampsia is one of the most common but the least understood multisystem disorder of pregnancy. Endothelial cell injury has been considered as the central feature of the pathology. Resultant endothelial cell dysfunction due to abnormal placentation and/or immunological and genetic disorders or cytotoxic factors may be implemented in the pathogenesis. 1, 2 Plasma thrombomodulin levels in very low birth weight (VLBW) infants at birth show high value and the main factor responsible for this elevation may be the endothelial damage or low clearance rate of thrombomodulin. 3 Thrombomodulin is an endothelial cell surface glycoprotein forming a complex with thrombin. Thrombomodulin bound to thrombin has no procoagulant activity but has a capability to activate protein C approximately 1000-fold faster than thrombin does alone. Activated protein C together with cofactor effect of protein S is a vitamin K-dependent serine protease that inactivates factor-Va and factor-VIIIa and neutralizes the tissue type plasminogen activator inhibitor. 4 Circulating thrombomodulin may be viewed as a marker of endothelium integrity and endothelial cell injury. 5 Plasma thrombomodulin levels are stable under physiological conditions and the effects of age and circadian rhythm on plasma thrombomodulin are negligible. Plasma thrombomodulin has been found to be increased in preeclampsia, which may be secondary to damage of vascular endothelium and syncytiotrophoblasts. 5, 6 Besides increased plasma thrombomodulin in thrombotic thrombocytopenic purpura, systemic lupus erythematosus, and disseminated intravascular coagulation have also been demonstrated as a consequence of damage to the vascular endothelium. 7 We studied plasma thrombomodulin levels in pregnancy-induced hypertensive disorders and investigated the possible correlations of plasma thrombomodulin with infants' birth weights and placental weights.
Materials and Methods
The study was conducted in the Department of Obstetrics and Gynecology of Trakya University, between the years 2003 and 2004, under the approval of Ethic Committee. Each participant signed informed consent. We recruited 80 pregnant women in their third trimester. Of these patients, 50 women comprised the study group (30 were with severe preeclampsia, 10 with HELLP syndrome, 10 with eclampsia) and 30 normotensive healthy pregnant women were accepted as controls. We excluded patients with chronic hypertension with or without superimposed preeclampsia, patients with a history of medical complications, and patients with placenta previa. The participants were matched for maternal age, gestational age, and parity. The mean + SD maternal age was 26.5 + 5.6 years in the preeclampsia group and 27.6 + 4.8 years in the controls, while the median gestational age was 32 to 33 weeks and the parity were comparable between the study and control groups.
The criteria for severe preeclampsia were blood pressure with !160 mm Hg systolic and/or !110 mm Hg diastolic and proteinuria (!2 g/24 h with dipstick or !2þ in a catheterized specimen). In addition, oliguria ( 400 mL in 24 hours), cerebral or visual disturbances, epigastric pain, pulmonary edema, abnormal platelet counts, and liver function studies were considered as evidence of severity in preeclampsia. The HELLP syndrome was defined as hemolysis [lactate dehydrogenase (LDH) ! 600 international unit (IU)/L, unconjugated bilirubin ! 1.2 mg/dL, elevated liver enzymes-aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ! 70 IU/L] and low platelets (platelet count 100 000/mm 3 ). The patients who experienced convulsions were considered as eclampsia. Systolic and diastolic blood pressure and proteinuria values were met by the criteria in the groups of HELLP syndrome and eclampsia and severe preeclampsia. The mean + SD diastolic blood pressure (mm Hg) values were 112.5 + 16.2 mm Hg in eclampsia (n ¼ 10), 114 + 14.2 mm Hg in HELLP syndrome (n ¼ 10), 111 + 11.5 mm Hg in severe preeclampsia (n ¼ 30), and 71.5 + 8.1 mm Hg in the controls (n ¼ 30).
All blood samples were obtained at the prepartum period within 24 hours of the deliveries and centrifuged at 2000g for 15 minutes at 4 C. Collected plasma samples were stored at À70 C until the assay was performed. Plasma thrombomodulin was measured with an enzyme immunoassay using a diagnostic thrombomodulin kit (Asserachrom, Diagnostica Stago, France) according to manufacturer's instruction. The plasma samples were incubated with thrombomodulin monoclonal antibodies and washed out. The enzyme activities were spectrophotometrically measured after adding horseradish peroxidase-labeled antithrombomodulin antibodies. The normal range for healthy controls was 30 to 44 ng/mL. Kruskal-Wallis statistical analysis was performed in comparison of descriptive and laboratory data (significance at P < .05). The correlation analysis and multiple comparisons between plasma thrombomodulin levels and birth weights and placental weights in disease and control states were done by analysis of variance (ANOVA) and Bonferroni tests (significance at P < .05).
Results
No statistically significant differences were noticed in the descriptive parameters such as maternal age, gestational age, and parity of the preeclamptics and matched controls. The systolic and diastolic blood pressure values and proteinuria of hypertensive disorders of pregnancy significantly differed from those of controls (P < .05). As to platelet counts of preeclamptics (209 500 + 88 250/mm 3 ) and controls (221 700 + 55 966/mm 3 ), significant difference was observed in the HELLP group (104 800 + 45 369/mm 3 ) compared to groups. Furthermore, the levels of ALT and AST of all preeclamptics (ALT 34.1 + 27.1 IU/L; AST 25.3 + 25.9 IU/L) were higher than the levels of normotensive controls (ALT 16.7 + 6.3 IU/L; AST 17 + 4 IU/L) and the level of liver enzymes in the HELLP group (ALT 292 + 225 IU/L; AST 189 + 168 IU/L) demonstrated more pronounced alterations. However, serum creatinine levels of the hypertensive group (0.8 + 0.4 mg/dL) were significantly higher than those of normotensive controls (0.5 + 0.1 mg/dL). All creatinine levels in hypertensive pregnant women were similar each other ( Table 1 ).
In the HELLP sydrome, the highest thrombomodulin levels (94.69 + 10.41 ng/mL) were associated with the lowest infant birth weight (1509.70 + 187.55 g) as well as the lowest placental weight (375.71 + 32.50 g) in the study population. Thrombomodulin in eclampsia (81.37 + 3.59 ng/mL) showed an association with infant birth weight (2078 + 132.65 g) and placental weight (495 + 32.95 g). Although the thrombomodulin level in severe preeclampsia was 67.15 + 3.72 ng/mL associated with the value 1748.20 + 132.62 g in infant birth weight and 385.50 + 25.08 g in placental weight, thrombomodulin levels of the control group demonstrated the mean (48.06 + 2.45 ng/ mL) with the highest infant birth weight (3228.85 + 84.83 g) and the highest placental weight (569.17 + 27.99 g) in the total group. The ANOVA analysis of thrombomodulin levels and infants' birth weights and placental weights exhibited highly significant difference (P ¼ .000) between the groups. However, in post hoc tests (Bonferroni test), all thrombomodulin levels and infant birth weights of hypertensive pathologies showed highly significant difference (P ¼ .000) according to control values. Excluding the placental weight in eclampsia, the other placentas also showed highly significant difference (P ¼ .005) in comparison to controls (Table 2) .
Finally, we might express that plasma trombomodulin levels could be a parameter determining severity and prognosis of the hypertensive pathologies.
Dscussion
Thrombomodulin is a natural anticoagulant widely distributed on the vascular endothelium of placenta. 4, 8 Under physiological conditions, thrombomodulin rises in maternal circulation as the pregnancy advances. 9 Elevated plasma thrombomodulin levels are also found due to endothelial cell damage in several disease states. 7 The present study supported the finding that infants' birth weights and placental weights correlated with elevated maternal plasma thrombomodulin levels in patients with severe forms of pregnancyinduced hypertension. This correlation was particularly evident in the patients who developed eclampsia and HELLP syndrome, with elevated thrombomodulin levels. In particular, the positive correlation between diastolic blood pressure and circulating thrombomodulin supported that the thrombomodulin might be a valuable marker for assessing the severity of the pathology and that could be regarded as secondary to preeclampsia-induced vascular endothelial damage. Observing no correlation between plasma thrombomodulin and serum creatinine level might directly reflect vascular endothelial damage rather than a decrease in renal clearance. Our results were supported by several researchers. Nako et al 3 observed high plasma thrombomodulin levels in VLBW infants at birth, but its pathogenesis was unclear. Wiwanitkit 10 stated considerable controversy regarding the clinical role of thrombomodulin as a risk factor in severe preeclampsia. From the retrospective analysis of the available 4 casecontrol studies on the thrombomodulin levels and their correlation to preeclampsia, the overall average thrombomodulin levels for the patients and controls were 66.7 + 11.9 and 45.7 + 7.3 ng/mL, respectively, which were significantly higher in patients than in controls (P < .05). Our range of the findings were similar to these results and the significance in the difference between controls and several states of hypertensive disorders in pregnancy was evident. Furthermore, infant birth weights at birth and placental weights were in concordance with these findings.
However, Shaarawy and Didy 5 emphasized that fibronectin might be a more valuable marker than thrombomodulin and plasminogen activator inhibitor (PAI-1) for assessment of vascular endothelial damage in preeclampsia and eclampsia. In the other study from Turkey, the serial determinations of thrombomodulin plasma levels were shown to be useful in determining severity and prognosis of preeclampsia. 11 Contrary to our findings, the elevated maternal serum thrombomodulin levels in severe preeclampsia were found to be positively correlated with creatinine and uric acid values. 12 It was suggested that elevated thrombomodulin levels in preeclampsia might reflect a decrease in renal clearance rather than in vascular endothelial damage. 12 However, we did not find any correlation between creatinine and thrombomodulin levels for all patients with preeclampsia. This finding further supported our hypothesis that increased thrombomodulin associated with decreased infant birth weight and placental weight was not secondary to renal pathology but was due to a damage in the vascular endothelium. Nevertheless, the increase in thrombomodulin levels should be regarded as a protection mechanism for the preeclampsia-induced endothelial alterations. The lectin-like domain of thrombomodulin was known to confer a protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor. 13 On the basis of these findings, elevated thrombomodulin levels with preeclampsia-induced endothelial alterations were associated with decreased infants' birth weights and placental weights.
